Educational content only. Not medical advice. Consult a qualified physician.
Tesamorelin Acetate peptide
Growth HormoneFDA-approved (Egrifta) for HIV-associated lipodystrophy. Off-label use for other indications is not FDA-approved.

Tesamorelin

Tesamorelin Acetate

Tesamorelin is a synthetic GHRH analog that is FDA-approved under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates pituitary GH release and has gained attention for off-label use in body composition optimization and potential cognitive benefits.
Reported Benefits

Potential Benefits

  • FDA-approved for reduction of visceral adipose tissue in HIV-associated lipodystrophy
  • Clinical trials demonstrated measurable reduction in trunk fat
  • Research suggests potential cognitive benefits, including improved executive function in older adults
  • Maintains physiologic pulsatile GH release pattern
  • May support improvements in lipid profiles based on clinical data
Research Dosing

Recommended Starting Dose

2 mg subcutaneously once daily (FDA-approved dose)

Based on published research protocols. Not a prescription.

Dosing Protocol

FDA-approved dosing is 2 mg injected subcutaneously into the abdomen once daily. Treatment duration in clinical trials ranged from 26-52 weeks. Periodic assessment of IGF-1 levels and glucose metabolism is recommended.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Clinical trials showed measurable reductions in visceral fat at 26 weeks. Some body composition changes may be noticed at 8-12 weeks.

Regulatory

Research Status

FDA-approved (Egrifta) for HIV-associated lipodystrophy. Off-label use for other indications is not FDA-approved.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Injection site reactions (erythema, pruritus, pain)
  • Joint pain (arthralgia)
  • Peripheral edema
  • Potential effects on glucose metabolism
  • Hypersensitivity reactions
  • May cause fluid retention
  • Not recommended during pregnancy
Related Research

More in Growth Hormone

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.